NewsBenzingaLongeveron宣布其laromestrocel用于治疗左心发育不良综合征婴儿的ELPIS II研究未能达到主要疗效终点，即右心室射血分数较基线的变化。 Longeveron宣布其laromestrocel用于治疗左心发育不良综合征婴儿的ELPIS II研究未能达到主要疗效终点，即右心室射血分数较基线的变化。 Benzinga 2026.10.26 13:18 (GMT+0) Open on Benzinga Other news Barclays Maintains Equal-Weight on Baidu, Lowers Price Target to $80 Nu Stock Crashes After Lula Defeats Bolsonaro in Runoff Barclays Maintains Equal-Weight on American Express, Lowers Price Target to $340 Evercore ISI Group Maintains In-Line on Park Hotels & Resorts, Raises Price Target to $17 Evercore ISI Group Maintains In-Line on Pebblebrook Hotel, Raises Price Target to $21 Evercore ISI Group Maintains Outperform on O'Reilly Automotive, Lowers Price Target to $110
